Previous 10 | Next 10 |
2024-05-02 15:10:06 ET More on Eli Lilly, Palatin Tech, etc. Eli Lilly Shoots Higher: It's Time To Be Cautious Eli Lilly: The GLP-1 Wonder Continues, A Bullish Beat And Raise Eli Lilly: Management Raises 2024 Guidance, Driven By GLP-1 Franchise GLP-1 drug pri...
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar ye...
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 PR Newswire CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (N...
2024-04-08 10:00:33 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Top ...
2024-04-08 09:49:02 ET More on Palatin Tech Palatin Technologies, Inc. 2024 Q1 - Results - Earnings Call Presentation Palatin Technologies, Inc. (PTN) Q2 2024 Earnings Call Transcript Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug Palatin Te...
2024-04-08 09:10:18 ET Auddia AUUD +123% on bagging a U.S. patent for the core AI technology it uses in its flagship faidr app to deliver ad-free AM/FM radio stations to paid subscribers. U Power ( UCAR ) +68% after the electric vehicle ( EV ) company announce...
2024-04-08 08:01:14 ET DENVER, Colo., Apr 08, 2024 ( 247marketnews.com )- Palatin Technologies, Inc. (NYSE: PTN ) presented positive Phase 3 PL9643 MELODY-1 clinical trial results for the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (...
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 PR Newswire Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primar...
2024-03-14 16:30:01 ET More on Palatin Tech Palatin stock plunges 40% on mixed Phase 3 data for dry eye drug Palatin Tech GAAP EPS of -$0.56 misses by $0.23, revenue of $2.03M beats by $0.27M Read the full article on Seeking Alpha For further details see: ...
A look at the top 10 most actives in the United States Marathon Digital Holdings Inc. (MARA) rose 2.4% to $31.03 on volume of 179,649,718 shares Vivani Medical Inc. (VANI) rose 270.3% to $3.74 on volume of 148,811,385 shares Nikola Corporation (NKLA) rose 1.7% to $0.7684 on volume of 121,...
News, Short Squeeze, Breakout and More Instantly...
Palatin Technologies Inc. Company Name:
PTN Stock Symbol:
NYSE Market:
Palatin Technologies Inc. Website:
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds PR Newswire CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing fi...
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) PR Newswire In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5...
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity PR Newswire Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end...